Target Price (Mid): ~$367Street Target: ~$283Potential Total Return: ~30%Annualized IRR: ~6% / yearWhat Happened?AbbVie (ABBV) presented primary Phase 2a results for ABBV-466, its investigational ...
Zacks Investment Research on MSN
BMY vs. ABBV: Which pharma/biotech stock offers more upside potential?
Bristol Myers Squibb BMY and AbbVie ABBV are two leading pharma/biotech players with diversified portfolios and a strong ...
AbbVie generates $17.8 billion in annual free cash flow but faces patent cliffs, while Vertex boasts a 33% net margin with ...
Foundational Pharmacy Strategies’ Christine Johnston on how rebate structures, pending legislation, and a stalled pipeline ...
Shares of Johnson & Johnson slid Tuesday after the pharma giant reported another solid but imperfect quarter. But with key ...
In the fiercely competitive inflammatory bowel disease (IBD) market, Eli Lilly is making the case for its antibody Omvoh as a ...
Omvoh met its Phase 3 pediatric ulcerative colitis endpoint, with 50 per cent remission among induction responders at one ...
AbbVie (NYSE: ABBV), a global pharmaceutical leader, and McLaren Racing today announced a multi-year partnership naming AbbVie an Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 ...
Together, the five positions generate $3,715 in annual passive income on a $100,000 investment, a blended yield of 3.72%. Realty Income contributes $1,208, Franklin Templeton adds $800, Chevron ...
From a pharma giant rebuilding after a blockbuster patent loss to a pipeline partnership targeting double-digit distribution raises through 2027, these five stocks span wildly different industries yet ...
At week 12, 60% of patients without prior advanced therapy failure had an endoscopic response, versus 15% on placebo; ...
AbbVie’s next-generation Crohn’s disease combination candidate has beaten Skyrizi in a midphase clinical trial. Skyrizi is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results